Chongqing Zhifei Biological Products Third Quarter 2024 Earnings: Misses Expectations

Chongqing Zhifei Biological Products (SZSE:300122) Third Quarter 2024 Results

Key Financial Results

• Revenue: CN¥4.53b (down 70% from 3Q 2023).
• Net loss: CN¥83.7m (down by 104% from CN¥2.27b profit in 3Q 2023).
• CN¥0.035 loss per share (down from CN¥0.95 profit in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Chongqing Zhifei Biological Products Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 65%. Earnings per share (EPS) was also behind analyst expectations.

Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's share price is broadly unchanged from a week ago.

Risk Analysis

Before we wrap up, we've discovered 3 warning signs for Chongqing Zhifei Biological Products (1 doesn't sit too well with us!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.